The introduction of chlorpromazine in 1953, and haloperidol in 1958, into clinical practice dramatically altered the therapy of schizophrenic patients. Although representing by no means a cure for this severe psychiatric ill ness, it allowed, for the first time, to adequately control the severe hallu cinations and delusional beliefs which prevent these patients from leading a more or less independent life. Indeed these antipsychotics (and the many congeners that were to follow) significantly reduced the number ofchronic schizophrenic inpatients in psychiatric clinics all over the world. However soon after their introduction it became clear that, like all other available drugs, antipsychotics were by no means miracle drugs. In fact, two major problems appeared. First, the antipsychotics had very little effect on the so-called negative or defect symptoms, like social isolation, apathy and anhedonia, and secondly virtually all antipsychotics produced a number of side-effects, of which the neurological (often called extra pyramidal) side-effects were the most troublesome. Especially the tardive dyskinesia, which occurred in about 15 to 20% of the patients after pro longed treatment, represented a major problem in the treatment of schizo phrenic patients.

This report is designed to raise the profile of mental illness in Canada among government & non-governmental organizations and the industry, education, workplace, & academic sectors. It describes major mental illnesses and outlines their incidence & prevalence, causation, impact, stigma, and prevention & treatment. Data presented are based on currently available provincial studies & data on mortality and hospitalizations. Five mental illnesses have been selected for inclusion in the report by virtue of their high prevalence rates or because of the magnitude of their health, social, & economic impact: mood disorders, schizophrenia, anxiety disorders, personality disorders, and eating disorders. While not in itself a mental illness, suicidal behaviour is also included since it is highly correlated with mental illness and raises many similar issues. The appendix includes information on data sources and a call for action on building consensus for a national action plan on mental illness & mental health.

The new edition of this popular handbook has been thoroughly updated to include the latest data concerning treatment of first-episode patients. Drawing from their experience, the authors discuss the presentation and assessment of the first psychotic episode and review the appropriate use of antipsychotic agents and psychosocial approaches in effective management.

50 Studies Every Psychiatrist Should Know presents key studies that have shaped the practice of psychiatry. Selected using a rigorous methodology, the studies cover topics including: psychotic disorders, depressive disorders, women's mental health, child and adolescent disorders, and epidemiological studies. This book is a must-read for health care professionals and anyone who wants to learn more about the data behind clinical practice.

The guideline offers clear, concise, and actionable recommendation statements to help clinicians to incorporate recommendations into clinical practice, with the goal of improving quality of care. Each recommendation is given a rating that reflects the level of confidence that potential benefits of an intervention outweigh potential harms.

Schatzberg's Manual of Clinical Psychopharmacology is a meticulously researched, yet down-to-earth guide for practitioners prescribing psychotropic medications to individuals with psychiatric disorders or symptoms mandating treatment. The ninth edition offers up-to-date information on current drugs, interactions, side effects, and dosing guidelines, and retains the strengths and features that have made it a standard text for trainees and practicing clinicians. The authors also include a new chapter on important developments in laboratory-guided pharmacotherapy, including pharmacogenomic testing, neurocognitive testing, quantitative EEG, and neuroimaging. Although the book's primary purpose is to provide the reader-practitioner with basic and practical information regarding the many classes of psychiatric medications, the authors stress that understanding how to select and prescribe psychotropic medications does not obviate the basic need to comprehensively evaluate and understand psychiatric patients. Accordingly, the book draws on the authors' clinical experience, as well as on the scientific literature, resulting in an accessible, yet rigorous text. Features that have helped cement this book's reputation include: Coverage is not limited to long-standing and newly approved medications, but also includes agents that are likely to receive approval from the FDA in the near future, ensuring that the reader stays up-to-date. References are provided for key statements, and each chapter is then followed by a list of selected relevant articles and books for readers who want to go beyond the material presented, making for a leaner, more reader-friendly guide. Dozens of summary tables with key information on classes of psychotropics function as quick-reference guides, promoting learning and serving as convenient resources for overloaded clinicians. The appendix offers two kinds of suggested readings. The first, for clinicians, is invaluable to trainees, while the second, for patients and families, helps point clinicians to books aimed at a lay audience to supplement information provided to patients. Staying abreast of both new medications and promising treatment protocols is essential in this rapidly evolving field. Schatzberg's Manual of Clinical Psychopharmacology delivers authoritative information in a friendly, collegial style, ensuring that both students and practicing clinicians are equipped to provide a superior standard of care.

This is the first book to address the clinical and neurobiological interface between schizophrenia and obsessive-compulsive disorder (OCD). There is growing evidence that obsessive-compulsive symptoms in schizophrenia are prevalent, persistent and characterized by a distinct pattern of familial inheritance, neurocognitive deficits and brain activation. This text provides guidelines for differential diagnosis of schizophrenic patients with obsessive-compulsive symptoms, and patients with primary OCD alongside poor insight, psychotic features or schizotypal personality. Written by a leading expert in the coexistence of obsessive-compulsive and schizophrenic phenomena, Schizo-Obsessive Disorder uses numerous case studies to present diagnostic guidelines and to describe a recommended treatment algorithm, demystifying this complex disorder and aiding its effective management. The book is essential reading for psychiatrists, neurologists and the wider range of multidisciplinary mental health practitioners.